Neuropathology/Neurohistology Assay

Neurological diseases, which occur in the central and peripheral nervous systems, including Alzheimer's disease, stroke, and spinal cord injury, impose an incalculable burden and death on humans worldwide. Assessment of the pathophysiology and histology of neurological diseases will be key to designing research methods and understanding and managing possible long-term effects of the disease on patients with neurological disorders. Creative Biolabs provides neuropathology/neurohistology assay services to global neurobiological scientists to support your projects.

Neurohistology Services

Creative Biolabs is committed to providing time and cost-effective brain research products and services for preclinical research on the central nervous system, focusing on various types of neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's diseases, ischemic stroke, and motor neuron disease (MND) including amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease and spinal cord injury (SCI).

Creative Biolabs provides the most reliable histological service, including:

• Tissue Sampling and Processing
• H&E Staining
• Whole Slide Imaging
• Section Scanning
• Immunohistochemical Services
• Immunofluorescence Services
• Clinical Pathology Service
• Toxicologic Pathology Service
• Ultramicropathology Services
• Histopathological Evaluation Services

Features of our Services

1. Neurohistological and neuropathological services of the central nervous system (CNS)
2. Neural staining kits
3. High-throughput digital microscopic imaging and stereology-based quantitative morphology
4. GLP and non-GLP studies.

Neurohistopathology Assay Showcase

Assay #1: Impact of AL002c treatment on microglia clustering around plaques and Spp1 production.

Fig. 1 Representative confocal images of Alzheimer's mouse hippocampus. Iba1 microglia (green), TO-PRO3-stained nuclei (red), and methoxy-X04-labeled aβ plaques (blue). (Mustafa, 2020)

Assay #2: Neuropathology of dementia.

Fig. 2 Visualization of β-amyloid and hyperphosphorylated tau using immunohistochemical staining. (Klotz, 2021)